Paradigm Biopharmaceuticals Ltd (OTCPK:PBIGF)
$ 0.1705 -0.0095 (-5.28%) Market Cap: 54.42 Mil Enterprise Value: 32.43 Mil PE Ratio: 0 PB Ratio: 2.45 GF Score: 29/100

Paradigm Biopharmaceuticals Ltd Investor Webinar Transcript

Aug 15, 2022 / NTS GMT
Release Date Price: $1.04 (-15.45%)
Operator

Thank you for standing by, and welcome to the Paradigm Biopharmaceuticals investor webinar today, discussing the capital raising being undertaken by the company. (Operator Instructions) Appearing on behalf of Paradigm today, we have the Chairman, Paul Rennie; CEO, Marco Polizzi; Chief Medical Officer, Dr. Donna Skerrett; and Director of Investor Relations, Simon White.

To begin, I'll hand it over to Paul. Please go ahead.

Paul Rennie
Paradigm Biopharmaceuticals Ltd. - Founder,Chairman & MD

Thank you, Matt. And just by way of introduction, I was asked to say a few words in relation to the capital raise. But before I present the details of the capital raise, could I just maybe position the capital raise with a few comments.

So we put this capital raise within context for our investors. So some people may think, why wouldn't we raise capital now? And as a lot of investors know, at our last quarterly webinar, we announced that we had four quarters of cash. So by definition, at the end of the next quarter, which will be the October report, it's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot